Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
August 01, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 Oral presentation...
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
April 04, 2022 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only treatment approved in the E.U. to...
Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
February 25, 2022 02:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma If approved by the European Medicines Agency,...
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
January 26, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanomaKIMMTRAK is the first and only FDA approved therapy for the treatment of...